Fine mapping and interaction analysis of a linear rabies virus neutralizing epitope.

A novel human antibody AR16, targeting the G5 linear epitope of rabies virus glycoprotein (RVG) was shown to have promising antivirus potency. Using AR16, the minimal binding region within G5 was identified as HDFR (residues 261-264), with key residues HDF (residues 261-263) identified by alanine replacement scanning. The key HDF was highly conserved within phylogroup I Lyssaviruses but not those in phylogroup II. Using computer-aided docking and interaction models, not only the key residues (Asp30, Asp31, Tyr32, Trp53, Asn54, Glu99, Ile101, and Trp166) of AR16 that participated in the interaction with G5 were identified, the van der Waals forces that mediated the epitope-antibody interaction were also revealed. Seven out of eight presumed key residues (Asp30, Asp31, Tyr32, Trp53, Asn54, Glu99, and Ile101) were located at the variable regions of AR16 heavy chains. A novel mAb cocktail containing AR16 and CR57, has the potential to recognize non-overlapping, non-competing epitopes, and neutralize a broad range of rabies virus.

• Publication year

  2010

• Venue

  Microbes and infection

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.micinf.2010.06.005PMID 20601078
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans

  2009cited by this paper
• Peptide mimotopes of rabies virus glycoprotein with immunogenic activity.

  2009cited by this paper
• Novel human 3-domain disulfide-stabilized antibody fragment against glycoprotein of rabies virus.

  2008cited by this paper
• Generation and characterization of human monoclonal antibodies to G5, a linear neutralization epitope on glycoprotein of rabies virus, by phage display technology

  2008cited by this paper
• Structure of the Prefusion Form of the Vesicular Stomatitis Virus Glycoprotein G

  2007cited by this paper
• Crystal Structure of the Low-pH Form of the Vesicular Stomatitis Virus Glycoprotein G

  2006cited by this paper
• Novel Rabies Virus-Neutralizing Epitope Recognized by Human Monoclonal Antibody: Fine Mapping and Escape Mutant Analysis

  2005cited by this paper
• Novel Human Monoclonal Antibody Combination Effectively Neutralizing Natural Rabies Virus Variants and Individual In Vitro Escape Mutants

  2005cited by this paper
• Identification of a conserved linear epitope at the N terminus of the rabies virus glycoprotein.

  2004cited by this paper
• Mapping of the Low pH‐Sensitive Conformational Epitope of Rabies Virus Glycoprotein Recognized by a Monoclonal Antibody #1‐30‐44

  2003cited by this paper
• Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies.

  2003cited by this paper
• Canine vaccine recipients recognize an immunodominant region of the rabies virus glycoprotein.

  2002cited by this paper
• Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1

  2001cited by this paper
• Evidence of Two Lyssavirus Phylogroups with Distinct Pathogenicity and Immunogenicity

  2001cited by this paper
• Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis.

  2001cited by this paper
• Rabies update

  2000cited by this paper
• Human rabies prevention -- United States, 1999 : recommendations of the Advisory Committee on Immunization Practices (ACIP)

  1999cited by this paper
• Human rabies prevention--United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

  1999cited by this paper
• Mass treatment of humans who drank unpasteurized milk from rabid cows--Massachusetts, 1996-1998.

  1999cited by this paper
• An Avirulent Mutant of Rabies Virus Is Unable To Infect Motoneurons In Vivo and In Vitro

  1998cited by this paper
• Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody.

  1998cited by this paper
• A virus-neutralizing epitope on the glycoprotein of rabies virus that contains Trp251 is a linear epitope.

  1997cited by this paper
• Mokola virus glycoprotein and chimeric proteins can replace rabies virus glycoprotein in the rescue of infectious defective rabies virus particles

  1995cited by this paper
• Mapping and Characterization of a Sequential Epitope on the Rabies Virus Glycoprotein Which Is Recognized by a Neutralizing Monoclonal Antibody, RG719

  1995cited by this paper
• Mechanisms of rabies virus neutralization.

  1993cited by this paper
• Structural and functional studies on a unique linear neutralizing antigenic site (G5) of the rabies virus glycoprotein.

  1993cited by this paper
• Antigenicity of rabies virus glycoprotein

  1991cited by this paper
• A Rabies-Specific Human Monoclonal Antibody That Protects Mice Against Lethal Rabies

  1991cited by this paper
• Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine

  1990cited by this paper
• Biological characterization of human monoclonal antibodies to rabies virus

  1990cited by this paper
• Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein.

  1989cited by this paper
• Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence

  1988cited by this paper
• Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein

  1985cited by this paper
• Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies.

  1984cited by this paper
• Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

  1984cited by this paper
• Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies.

  1983cited by this paper
• Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus.

  1983cited by this paper
• Structure and molecular biology of rabies virus.

  1976cited by this paper

• Generation and Selection of Novel Human-Neutralizing Single Chain Variable Fragments Against Rabies Virus from Immunized Phage Display Libraries

  2025cites this paper
• Rabies vaccine: progress and prospective

  2023cites this paper
• Research progress on neutralizing epitopes and antibodies for the Rabies virus

  2022cites this paper
• Analysis of the evolution, infectivity and antigenicity of circulating rabies virus strains

  2022cites this paper
• Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups

  2020cites this paper
• Origins of the arctic fox variant rabies viruses responsible for recent cases of the disease in southern Ontario

  2019cites this paper
• Characterization of epitopes on the rabies virus glycoprotein by selection and analysis of escape mutants.

  2016cites this paper
• Immunogenicity of multi-epitope-based vaccine candidates administered with the adjuvant Gp96 against rabies

  2016cites this paper
• Design, construction and expression of recombinant vector containing the rabies virus nucleoprotein gene

  2014cites this paper
• Genetic characterization and phylogenetic analysis of skunk-associated rabies viruses in North America with special emphasis on the central plains.

  2013cites this paper
• Conservation of Binding Epitopes for Monoclonal Antibodies on the Rabies Virus Glycoprotein

  2013influential citation